Avacta Appoints Francis Wilson As Chief Scientific Officer
09 Feb 2026 //
GLOBENEWSWIRE
FDA Clears Avacta`s IND Application for AVA6103 (FAP-Exatecan)
21 Jan 2026 //
GLOBENEWSWIRE
Avacta Announces Year-End Trading Update
20 Jan 2026 //
GLOBENEWSWIRE
AVA6000 Phase 1b Trial Shows Tumor Shrinkage in Salivary Cancers
17 Dec 2025 //
GLOBENEWSWIRE
Avacta Shares 1st Clinical Data on Dual Payload pre|CISION Drugs
25 Oct 2025 //
GLOBENEWSWIRE
Avacta Unveils Strong Phase 1A Results For Faridoxorubicin
19 Oct 2025 //
GLOBENEWSWIRE
Avacta To Reveal Dual Payload Pre|Cision Data At Conference
13 Oct 2025 //
GLOBENEWSWIRE

Market Place
Sourcing Support